AstraZeneta's all-out over-the-top drug sales are being monitored.

Pharmaceutical Network August 31st, August 20th, the third round of national collection in Shanghai opened the bid.
from 194 pharmaceutical companies gathered at the Longbai Hotel.
pharmaceutical companies stuffed printed quotations into designated envelopes, handed them over to the organization staff, and entered the conference hall in batches.
the afternoon of the 20th, the collection of all the attention officially opened.
each turn, the host opens the envelope and bids for each drug factory.
results soon came out, Chinese pharmaceutical companies to low-cost advantages, almost crushed foreign pharmaceutical companies.
AstraZeneta was one of those crushed, with all four bidding drugs failed.
, one of the company's drugs by the Fujian Health Insurance Bureau included in the key monitoring, sales crisis mountain rain to come.
four drugs were all lost in AstraZeneta's bid for the drugs, including anatrophic tablets, omeprazole intestinal capsules, pyrithion tablets, and tigrillo tablets.
results showed that AstraZeneta had all failed to bid.
the rules of collection are very clear, follow the principle of low price, bidding pharmaceutical companies first self-quote, the organization collected after the ticket disclosure, low-priced pharmaceutical companies (quantity range) to get the order, that is, the winning bid.
offer from AstraZeneta is far higher than that offered by competing Chinese drug companies.
Take the Grelo tablets as an example, Shanghai Huilun Jiangsu Pharmaceuticals, Shi Medicine Ohyi, Zhengda Tianqing and other winning bids, give a price in the 0.36 yuan - 1.5 yuan range;
this practice is not an isolated case in foreign pharmaceutical companies on the same day.
international giants have offered high prices and appear to have offered to drop their bids.
even CRO (pharmaceutical outsourcing) personnel appear on the scene, many in the industry speculate whether these outsourcing is hired by foreign pharmaceutical companies, to go on the ground.
the international giants, the significance is diminishing as a result of the bidding process.
July 30, AstraZeneta released its 2020 half-yearly report.
, a key product, reported sales of $147m in the first half of the year, down 42 per cent from a year earlier.
emerging market, where china is located, with sales of $120m in the same period, down 27 per cent year-on-year.
ginistinib for AstraZeneone's 2019 collection of the winning drugs, the same period the winning bid is also Zhengda Qing, Qilu Pharmaceuticals.
data show that Qilu Pharmaceuticals, Zhengda Tianqing, AstraZeneta's winning bid price is 25.7 yuan / piece, 45 yuan / piece, 54.7 yuan / piece.
In the past, foreign pharmaceutical companies because of patent protection, a considerable period of time can enjoy the domestic market;
, even if foreign pharmaceutical companies win the bid to get the size of the order, must also let the unit price.
AstraZeneta's Gifeitini, which had a maximum price of more than 150 yuan per piece, and last year won the bid of 54.7 yuan per piece.
fall in unit prices overflying Chinese drug companies, foreign drug sales have fallen, it is difficult to avoid.
to this, the reporter on whether Gifeitini's sales in China serious decline, whether to actually give up the collection channels and other issues, called AstraZeneone's Shanghai station, but has not been answered.
drug is the focus of the Health Insurance Bureau to monitor the sale of gold, has always been a topic that pharmaceutical companies can not get around, whether domestic or foreign investment.
July 31, the Fujian Provincial Health Insurance Bureau issued a Notice on the Publication of the First Batch of Health Insurance Focused Monitoring Drugs and Focusing on Drug Lists.
for the marketing of medical insurance drugs in hospital terminals, there may be gold sales, commercial bribery and other issues, to be checked.
list of the two subjects, the number is 10, 43 respectively.
AstraZeneone's injections with sodium omeprazole are on the list, and three other drugs are on the list.
A foreign pharmaceutical company source revealed that the focus is because the local sales of drugs are better, included in the daily inspection;
assalicon on the list of key monitoring of the injection of sodium omeprazole, introduced in China in 2007.
domestic pharmaceutical companies such as Osaikang have the same listed drugs, but sales can not be compared with AstraZeneta.
2018 domestic hospital terminal sales reached 2.8 billion yuan, according to the company's internal network data.
, However, AstraZeneta's sales will be greatly reduced after being monitored.
, the drug was yellow-labeled on the Fujian Provincial Health Insurance Bureau's procurement platform, and its sales and health insurance usage were limited to a red line.
to this, the reporter on the injection of omeprazole sodium whether there is commercial bribery to AstraZeneone, but never replied.
the mountains and rain to wind the building.
9 domestic pharmaceutical companies, such as Zhengda Qingtian, Hesco, etc., have submitted to the Drug Administration the same drug consistency evaluation.
the process, these pharmaceutical companies can apply for listing after evaluation.
, if the drug starts harvesting, AstraZenecom will continue its current strategy, losing 2.8 billion yuan of market share, will be a high probability event.
regulatory storm that has forced AstraZeneta to make adjustments to its research and development, sales and other business units.
, AstraZeneta signed an agreement with Kantai Bio.
has been awarded domestic development rights for AstraZeneta's new crown vaccine, AZD1222, including research and development, production, supply and commercialization.
as the new crown epidemic rages, AstraZeneta and international pharmaceutical companies such as Pfizer, Novartis and Moderna are competing on the track to develop vaccines.
, in addition to the National Pharmaceutical Group and university research institutions, private enterprises are difficult to cut in.
, in other words, working with AstraZeneta is a boon to Kantai.
, as a drug company with strong research and development and sales, AstraZeneta's easy abandonment of the Chinese market has somewhat surprised the industry.
a reason AstraZeneta gave up, according to the company, was probably a lack of confidence in the sales team and possible layoffs within the marketing community.
in December 2018, when Mr Lai was promoted to general manager of AstraZeneta China, he made major changes to the internal structure: only three of the seven sales areas of the Diabetes business were retained and the remaining four were merged into other business units.
round of changes, sales staff actually shrink.
streamlined sales team has become the choice of many foreign pharmaceutical companies.
generally speaking, foreign pharmaceutical companies divide their departments according to their areas of expertise, such as cardiovascular, diabetes, vaccines, etc.
when a drug's poor performance leads to a decline in division-wide profits, the company considers cutting back by merging with other divisions or selling drug development rights to domestic pharmaceutical companies.
no matter which way, for sales, nothing more than leaving or transferring jobs.
, especially in the context of the collection of lost targets, foreign pharmaceutical companies gradually set their sights on pharmacies, to expand sales have long been interested in Xingshan.
. Data from Ai Kunwei, a U.S. statistics firm, show that after last year's harvest, the proportion of foreign-funded raw drugs that failed to attract the winning bid rose from 38% to 46% at the domestic retail end (mainly pharmacies), and the number of winning varieties fell from 15% to 9%.
Lilac Garden Forum has patients said that when doctors open a drug list, there is a winning set of domestic drugs, will also inform foreign drugs, if foreign drugs cheaper than before, will go to the pharmacy to buy.
, many foreign-funded pharmaceutical companies will retain more seniority sales, focus on doctor resources, prompting patients to go to pharmacies to buy drugs.
not only avoids the sale of money to encroach on health insurance, but also reduces labor costs.
.